The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law FDA considers adding a dozen peptides to its bulk drug compounding list RAPS Mitigating Risks of Compounded Drugs Through Surveillance FDA